Anti-CD45 CAR T-cell therapy(Perelman school of medicine)

N/A

Report date: 2023/11/08 17:26:18

Base Information

Drug NameAnti-CD45 CAR T-cell therapy(Perelman school of medicine)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD45T lymphocyte replacements

TargetsLeukocyte common antigen

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania Perelman School Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pennsylvania Perelman School Of Medicine

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A